CellaVision AB (CEVI.ST) stock: key figures, P/E, revenue and dividend
Health Care · Health Care Equipment · Sweden · ISIN SE0000683484
CellaVision AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 723.22 m SEK | 758.97 m SEK |
| Gross profit | 487.07 m SEK | 519.88 m SEK |
| Operating income | 177.68 m SEK | 202.07 m SEK |
| EBIT | 185.02 m SEK | 204.98 m SEK |
| Net income | 140.72 m SEK | 153.08 m SEK |
| Diluted EPS – continuing operations | 5.90 SEK | 6.42 SEK |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CellaVision AB
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company's CellaVision Bone Marrow Aspirate Application enables laboratories to automate, standardize, and simplify morphological examination of bone marrow aspirate samples; CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas, a library of blood cell images and descriptions created by digital cell morphology experts; CellaVision Review Software removes restrictive constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.
More stocks
- Simei Media Co Ltd (002712.SZ)
- Qinghai Huzhu Barley Wine Co Ltd (002646.SZ)
- Jiangxi Chen Guang New Materials Co Ltd (605399.SS)
- BitGo Holdings, Inc. (BTGO)
- Neosem Inc (253590.KQ)
- KELLY SERVICES INC (KELYA)
- ScinoPharm Taiwan Ltd (1789.TW)
- Shanghai Rychen Technologies Co. Ltd. A (301273.SZ)
- Jiangsu Xiuqiang Glasswork Co (300160.SZ)
- GB Group PLC (GBG.L)
- Gresgying Digital Energy Technology Co Ltd (600212.SS)
- Penyao Environmental Protection Co Ltd Class A (300664.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.